Amneal Pharmaceuticals (AMRX) Other Accumulated Expenses (2018 - 2026)

Amneal Pharmaceuticals' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 75.75% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (down 75.75% YoY), while the FY2025 annual figure was $43.3 million, up 36.22% from the prior year.
• Other Accumulated Expenses was $10.5 million for Q1 2026 at Amneal Pharmaceuticals, down from $43.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $275.3 million in Q2 2022 to a low of $10.5 million in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $73.0 million across 5 years, with a median of $43.4 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Other Accumulated Expenses surged 85.32% in 2022, then tumbled 75.75% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $107.5 million in 2022, then dropped by 28.37% to $77.0 million in 2023, then slumped by 58.75% to $31.8 million in 2024, then jumped by 36.22% to $43.3 million in 2025, then slumped by 75.61% to $10.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $10.5 million (Q1 2026), $43.3 million (Q4 2025), and $40.6 million (Q3 2025), per Business Quant data.